{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Mai N"],"funding":["NCI NIH HHS"],"pagination":["92"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11489574"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["10(1)"],"pubmed_abstract":["After disease progression on endocrine therapy (ET) plus a CDK4/6 inhibitor, there is no standardized sequence for subsequent treatment lines for estrogen receptor positive (ER+) metastatic breast cancer (MBC). CDK4/6i retrial as a treatment strategy is commonplace in modern clinical practice; however, the available prospective data investigating this strategy have had inconclusive results. To frame this data in a real-world context, we performed a retrospective analysis assessing the efficacy of CDK4/6is in 195 patients who had previous exposure to CDK4/6i in a prior treatment line at our institution. Among patients who had stopped a CDK4/6i due to toxicity, CDK4/6i retrial either immediately after with a different CDK4/6i or in a further treatment line with the same initial CDK4/6i was b"],"journal":["NPJ breast cancer"],"pubmed_title":["Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer."],"pmcid":["PMC11489574"],"funding_grant_id":["P30 CA008748"],"pubmed_authors":["Norton L","Razavi P","Mai N","Modi S","Chandarlapaty S","Jhaveri K","Dos Anjos CH","Robson M","Drago JZ","Dang CT","Patil S","Safonov A","Chen Y","Liu D","Bromberg JF"],"additional_accession":[]},"is_claimable":false,"name":"Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer.","description":"After disease progression on endocrine therapy (ET) plus a CDK4/6 inhibitor, there is no standardized sequence for subsequent treatment lines for estrogen receptor positive (ER+) metastatic breast cancer (MBC). CDK4/6i retrial as a treatment strategy is commonplace in modern clinical practice; however, the available prospective data investigating this strategy have had inconclusive results. To frame this data in a real-world context, we performed a retrospective analysis assessing the efficacy of CDK4/6is in 195 patients who had previous exposure to CDK4/6i in a prior treatment line at our institution. Among patients who had stopped a CDK4/6i due to toxicity, CDK4/6i retrial either immediately after with a different CDK4/6i or in a further treatment line with the same initial CDK4/6i was b","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Oct","modification":"2025-04-04T02:54:37.554Z","creation":"2025-04-04T02:54:37.554Z"},"accession":"S-EPMC11489574","cross_references":{"pubmed":["39424631"],"doi":["10.1038/s41523-024-00699-3"]}}